Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

Final results from PALLAS: adjuvant palbociclib in HR+/HER2- early breast cancer [Video]

Michael Gnant, MD, Medical University of Vienna, Vienna, Austria, shares the final results from the randomized, Phase III PALLAS trial (NCT02513394). PALLAS investigated whether the addition of the CDK4/6 inhibitor, palbociclib, to adjuvant endocrine therapy improves outcomes over endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early breast cancer. The addition of palbociclib did not improve survival endpoints in this patient population; whether the addition of CDK4/6 inhibition to particular subgroups of patients is being investigated. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

MASTER: Dara-KRd in patients with multiple myeloma [Video]

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses findings from the Phase II MASTER trial (NCT03224507), which investigated daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) followed by autologous transplantation in patients with newly diagnosed multiple myeloma (MM). Patients additionally received Dara-KRd consolidation based on minimal residual disease (MRD) status, with the primary endpoint being MRD negativity. A majority of the cohort achieved a complete response and MRD negativity, but progression-free survival was lower in patients with ultra-high risk MM. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Concurrent pembrolizumab and chemotherapy in classical Hodgkin lymphoma [Video]

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses concurrent pembrolizumab, an anti-PD⁠-⁠1 monoclonal antibody, with AVD (doxorubicin, vinblastine, and dacarbazine) in patients with classical Hodgkin lymphoma (cHL). The treatment regimen displayed promising efficacy and safety and in patients. However, the interim-positron emission tomography (PET) scan results did not align with the high progression-free survival rates observed, and cell-free DNA (cfDNA) may predict outcomes more accurately. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

Molecular heterogeneity in HER2+ breast cancer and predicting outcomes [Video]

Aleix Prat, MD, PhD, Hospital Clinic Barcelona, Barcelona, Spain, provides an overview of molecular heterogeneity in HER2+ breast cancer, discussing biological features linked to clinical outcomes including intrinsic subtyping. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Blood Cancer

Treating TP53 mutant mantle cell lymphoma in the BOVen trial [Video]

Patients with TP53 mutant mantle cell lymphoma (MCL) represent an unmet need and there care no current frontline standard of care for these high risk patients. Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, presents results from the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant MCL. Two cycles of zanubrutinib and obinutuzumab were initially administered, followed by venetoclax. The regimen was well tolerated and displayed preliminary efficacy, with a majority of patients being in ongoing remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Maintenance nivolumab in post-stem cell transplant Hodgkin lymphoma [Video]

Nirav N. Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses data from the single-arm Phase II trial (NCT03436862) of nivolumab, an anti-PD-1 monoclonal antibody, as maintenance therapy in patients with Hodgkin lymphoma who have undergone autologous stem cell transplant. Maintenance brentuximab is currently the standard of care and 37 patients were enrolled in the trial to receive nivolumab. Whilst some patients discontinued treatment due to adverse events, progression-free survival was 92.1% and overall survival was 100% after a 9 month follow-up. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

ZUMA-7: Axi-cel in r/r large B-cell lymphoma [Video]

Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, presents results from the Phase III ZUMA-7 trial (NCT03391466) which assessed axicabtagene ciloleucel (axi-cel), an autologous anti‑CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). 359 patients either received axi-cel or the standard of care, with the primary endpoint being event-free survival (EFS). After a 24 month follow-up, patients in the axi-cel arm demonstrated a superior EFS and overall response rate (ORR). Overall survival (OS) was additionally superior in the axi-cel arm, but was not statistically significant. The results suggest axi-cel can be a second-line treatment for r/r LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Breast Cancer

AMEERA-5: amcenestrant + palbociclib for previously untreated ER+/HER2- advanced breast cancer [Video]

Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the on going AMEERA-5 study (NCT04478266), a randomized double-blind Phase III study of amcenestrant plus palbociclib versus letrozole and palbociclib for previous untreated ER+/HER2- advanced breast cancer. Amcenestrant is an oral SERD that antagonizes and degrades the estrogen receptor (ER) resulting in inhibition of the ER signaling pathway. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

TROPION-PanTumor01: datopotamab deruxtecan in advanced HER2+ breast cancer [Video]

Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the updated results from TROPION-PanTumor01 (NCT03401385), a Phase I study evaluating datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. Dato-DXd was demonstrated promising antitumor activity with a manageable safety profile in patients with previously treated advanced/metastatic triple-negative breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

ALTERNATE: neoadjuvant endocrine treatment in ER+/HER2- breast cancer [Video]

Cynthia X. Ma, MD, PhD, Washington University in St. Louis, St. Louis, MO, discusses the results of the ALTERNATE study (NCT01953588), an Alliance trial evaluating Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancer [Video]

Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses results from the Phase III randomised EMERALD trial (NCT03778931), investigating the novel oral selective estrogen receptor (ER) degrader, elacestrant, compared to standard of care (SOC) endocrine therapy for patients with ER+ HER2- metastatic breast cancer. Primary endpoints were progression-free survival (PFS) in the overall patient population and in patients with ESR1 mutation. The trial reported a 30% reduction in risk of progression or death in the overall progression, which rose to 45% in patients with ESR1 mutation, compared to SOC. The main side effect was nausea, which was more severe for patients receiving elacestrant than those receiving SOC. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.